Pharvaris (NASDAQ:PHVS) Given Average Rating of "Buy" by Analysts

Shares of Pharvaris (NASDAQ:PHVS - Get Free Report) have earned a consensus recommendation of "Buy" from the five analysts that are currently covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $36.20.

Several equities analysts have recently commented on PHVS shares. Cantor Fitzgerald reduced their target price on Pharvaris from $28.00 to $25.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Guggenheim started coverage on shares of Pharvaris in a report on Wednesday. They issued a "buy" rating and a $32.00 price target on the stock. Finally, Wedbush reissued an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a report on Thursday, June 5th.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently made changes to their positions in the company. FMR LLC boosted its holdings in Pharvaris by 3.6% in the fourth quarter. FMR LLC now owns 5,395,370 shares of the company's stock worth $103,429,000 after purchasing an additional 189,714 shares during the period. Soleus Capital Management L.P. grew its position in shares of Pharvaris by 36.2% during the 4th quarter. Soleus Capital Management L.P. now owns 814,652 shares of the company's stock valued at $15,617,000 after buying an additional 216,483 shares during the last quarter. Octagon Capital Advisors LP raised its stake in Pharvaris by 25.4% during the fourth quarter. Octagon Capital Advisors LP now owns 778,000 shares of the company's stock worth $14,914,000 after acquiring an additional 157,530 shares during the period. Rock Springs Capital Management LP raised its position in shares of Pharvaris by 2.4% during the 4th quarter. Rock Springs Capital Management LP now owns 775,131 shares of the company's stock worth $14,859,000 after purchasing an additional 18,200 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Pharvaris by 36.4% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 443,896 shares of the company's stock worth $8,510,000 after purchasing an additional 118,408 shares during the last quarter.

Pharvaris Trading Up 0.3%

NASDAQ:PHVS traded up $0.05 on Wednesday, reaching $17.10. The stock had a trading volume of 3,990 shares, compared to its average volume of 60,340. The company has a 50-day moving average of $15.75 and a 200 day moving average of $17.00. The stock has a market cap of $894.16 million, a P/E ratio of -6.11 and a beta of -2.86. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.09). On average, equities analysts predict that Pharvaris will post -2.71 EPS for the current year.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.